Related Experiment Video

Updated: Aug 22, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Proinflammatory cytokine levels in patients with diastolic heart failure

Ekaterina Nikolaevna Amosova1, Yaroslav Vladimirovich Shpak, Anna Vasiljevna Nedozhdij

  • 1National Medical University, Kiev, Ukraine.

Kardiologia Polska
|September 1, 2004
PubMed

Insights

Tumor Necrosis Factor-alpha (TNFa) and Interleukin-6 (IL-6) are elevated in diastolic heart failure (HF). Higher TNFa levels correlate with more severe HF, indicating its role in diastolic dysfunction.

Area of Science:

  • Cardiology
  • Immunology
  • Biochemistry

Background:

  • Cytokine roles in systolic heart failure (HF) are known, but their involvement in diastolic HF remains unclear.
  • Investigating inflammatory markers in diastolic HF is crucial for understanding its pathogenesis.

Purpose of the Study:

  • To determine serum levels of Tumor Necrosis Factor-alpha (TNFa) and Interleukin-6 (IL-6) in patients with diastolic HF.
  • To assess the association between these cytokine levels and the severity of left ventricular (LV) diastolic dysfunction and functional class.

Main Methods:

  • Serum samples from 26 diastolic HF patients and 10 healthy controls were analyzed for TNFa and IL-6 using ELISA.
  • Echocardiography assessed LV systolic and diastolic function, septal and posterior wall thickness, end-diastolic size, and left atrial volume.

Main Results:

  • TNFa and IL-6 levels were significantly elevated in diastolic HF patients compared to controls.
  • Elevated cytokine levels were observed across different types of LV diastolic dysfunction (impaired relaxation, restriction/pseudonormalization).
  • Higher TNFa levels correlated with more severe diastolic dysfunction and higher NYHA functional class (III-IV vs. II), and with increased left atrial volume.

Conclusions:

  • Serum TNFa and IL-6 levels are elevated in patients with diastolic HF.
  • TNFa elevation is linked to the severity of diastolic HF, as indicated by NYHA class, LV diastolic dysfunction type, and left atrial volume.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...